Royalty Report: Drugs, Drug Discovery, Assay – Collection: 332263

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Drug Discovery
  • Assay
  • Disease
  • Therapeutic
  • Test/Monitoring
  • Data Management
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 332263

License Grant
Included with this collaboration agreement is a third party license.  The collaboration is to screen the Materials against the Assays.

This third party grants the use of the assay.

License Property
Licensor has certain technology utilized by Licensee in all current Combinatorial Libraries.

Hexapeptide Combinatorial Libraries
Four (4) hexapeptide libraries (L, D, acetylated L'and D) are available'· All libraries have the first ·two positions fixed with the remaining four positions consisting or'equimolar mixtures. Proof of concept has been broadly demonstrated· and· potent lead peptfcies identified. Each library contains 52 million peptides.

Tetrapeptide Combi~atorial Libraries.
Three (3) tetrapeptide l'ibraries are available. Two of the tetrapeptide libraries (one nonacetylated and the other·acetylated) contain combinations of 75 different amino acids (L, D and unnatural). Both libraries have the first position fixed with the remaining three positions consisting of equimolar mixtures. Proof of concept has been demonstrated. Each of these libraries contain approximately 30 million peptides.

Field of Use
Licensee provides combinatorial libraries to the Licensor and the Licensor screens such combinatorial libraries against hybrid yeast cells for the purpose of identifying candidates for drug development.

The Parties commenced a joint discovery effort, with acute inflammation as the initial therapeutic focus for the collaboration.

IPSCIO Record ID: 332264

License Grant
Included with this collaboration agreement is a third party license.  The collaboration is to screen the Materials against the Assays.

This third party grants the use of the technology.

License Property
Licensor has patent rights which generally apply with respect to identifications from utilization of most Combinatorial Libraries.
Field of Use
The joint discovery effort isfor  acute inflammation as the initial therapeutic focus for the collaboration.

IPSCIO Record ID: 222558

License Grant
For the Compounds and Products, Licensor grants an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology, exclusive even as to Licensor and its Affiliates, to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory. It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

For the Collaboration Target-Specific Technology, Licensor grants an exclusive license, exclusive even as to  Licensor and its Affiliates, under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

For the Collaboration Platform Technology, upon conclusion of the Collaboration Term, the Parties each  grant, to the other a co-exclusive license under their respective interests in the Collaboration Platform Technology in the Territory, as follows  the Parties may each use such Collaboration Platform Technology for any and all internal uses, including without limitation, in collaboration with Third Parties for drug discovery.

For the Columbia Sublicense, Licensor grants a non-exclusive sublicense, without the right to sublicense, under the Columbia License, to make, have made, use, offer to sell, sell, import and export Agreement Products in the Territory, including, without limitation, the right to decode Library Compounds.

License Property
Licensor has developed proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.  'Licensor Technology' shall mean Existing Licensor Patent Rights, Existing Licensor Know-How, and Licensor Improvements (with some exceptions).

Product means any Agreement Product or Licensees Product.

Agreement Product shall mean any product containing an Agreement Compound, including, without limitation, products for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings or animals.

Licensees Product shall mean any product for the therapeutic or prophylactic treatment or prevention of diseases and conditions in human beings containing a Licensee Compound, provided such Licensee Product is not a Combination Product containing both a Licensee Compound and an Agreement Compound.

Active Compound shall mean a Library Compound that demonstrates activity against a specific Target, which Library Compound was found to have such activity at a concentration set forth in the applicable Collaboration Research Plan during screening of one or more Libraries by Licensor in the conduct of the Collaboration or was found to have such activity during screening by or on behalf of Licensee.

Licensor's combinatorial chemistry technology as an important component in our ongoing efforts to accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.'

Field of Use
This agreement field relates to assays, compound screening methods and biological research tools used to design, prepare and screen compound libraries against Licensees biological targets.

IPSCIO Record ID: 222557

License Grant
Licensor agrees to grant, and hereby grants to Licensee an exclusive license under the Licensor Technology and Licensors interest in the Collaboration Technology (exclusive even as to Licensor and its Affiliates), to make, have made, use, sell, offer to sell, import and export Agreement Products in the Territory.  It is understood that such licenses shall include the right to conduct drug research and development, and the exclusive right to discover, develop, make, have made and use Agreement Compounds, during the term of this Agreement.

Licensor agrees to grant, and hereby grants, to Licensee an exclusive license (exclusive even as to Licensor and its Affiliates), under all of Licensors interest in the Collaboration Target-Specific Technology for any and all purposes in the Territory, including the right to grant sublicenses.

License Property
The proprietary technologies relating to the design and preparation of encoded compound libraries based upon combinatorial chemistry.

Combination Product shall mean a Product which comprises two (2) or more active therapeutic ingredients at least one (1) of which is an Agreement Compound or a Licensee Compound.

Library Compound shall mean any compound which is contained in a Discovery Library or Optimization Library hereunder.

Target shall mean a biomolecular entity (including, without limitation, receptors, enzymes, nucleic acids and proteins, and/or fragments thereof) that a small molecule is screened against in order to determine whether the small molecule demonstrates a specific biochemical or pharmaceutical effect.

Library shall mean any chemical compound library prepared by Licensor employees working on the Collaboration, and/or Licensee employees working at Licensors facilities on the Collaboration,  under the terms of this Agreement using (i) combinatorial chemistry techniques or (ii) such other techniques as may, from time to time, be agreed by the Parties.

Field of Use
This agreement pertains to the drug industry relating to therapeutic, treatment or prevention of diseases and conditions in human beings.

Licensor's combinatorial chemistry technology will accelerate the drug discovery process and to identify lead compounds for development as new therapeutic entities.

IPSCIO Record ID: 329676

License Grant
For the license grant for Exclusive Screens Licensor grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice the Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee.

For the license grant for Non-Exclusive Screens, License grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice Non-Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee, during the term of the Research Programs, but in no event for less than nine months after Licensee receives Materials and other information from Licensor identifying and enabling Licensee to use such Non-Exclusive Screen.

License Property
Licensor has the exclusive rights to certain technology involving the transfection and expression of G-protein- coupled receptors into yeast.  Licensor exploits similarities between the yeast and human genome to identify new drug discovery targets.

The Autocrine System shall mean that part of Licensors Technology whereby any yeast cells into which human Receptors have been inserted and grow in response to compounds produced and secreted by the same yeast cells.

Compound shall mean any Lead Compound or any Analog of any Lead Compound.

Receptor shall mean any human, G-protein-coupled, seven transmembrane receptor (including, without limitation, genes, vectors and cDNAs), and shall include any Licensee Receptor or Other Receptor.

Licensee Receptor shall mean a Receptor which is proprietary to Licensee and is provided by Licensee to Licensor for use in the Research Programs, or a Receptor which is proprietary to Licensee and is cloned or obtained by Licensor pursuant to research performed under the Research Programs, or a Receptor provided by Licensee to Licensor for use in the Research Programs which is deemed to be a Licensee Receptor.

Technology shall mean all inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, Patents and Know-How owned by Licensor or to which Licensor has the rights to grant licenses or sublicenses, and relating to or derived from Licensors yeast-based, human G-protein-coupled receptor technology, or the Research Programs.

The Patents are titled
Expression of G Protein Coupled Receptors in Yeast, Yeast-Based Peptide Libraries for identification of G Protein-Coupled Receptor Agonists and Antagonists, and, Functional Expression of Mammalian Adenylyl cyclase in Yeast.

Field of Use
The field of use is screening assays.

Licensee recognizes that the technology represents a valuable source of development of screening assays for the discovery of potential products for manufacture, use and sale in the Territory.

IPSCIO Record ID: 243481

License Grant
The Licensor of the United Kingdom and Licensee wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

The United Kingdom Licensor grants an exclusive license, under the Licensor Patents and under Licensor Know-How, to make, have made, use, import, offer to sell, sell and have sold Products in the Territory. Licensor also grants the right to sublicense.

This agreement also includes a non-exclusive grant back to the Licensor.

License Property
The Licensors library consists of Millions of compounds for potential use in high throughput screening are available for purchase from commercial suppliers.  Licensor has used state-of-the-art molecular design software to analyse these commercial compound libraries both for chemical diversity and drug potential, which are critical parameters in developing novel lead compounds. On the basis of these analyses, Licensor has purchased a unique set of chemically diverse, drug-like molecules. Licensors library has also been selected to avoid poor chemical starting points for drug design. The Licensor Library currently contains approximately 50,000 compounds and all of these will be evaluated in the hepC polymerase primary assay.  Compounds which demonstrate activity in the primary assay, will be defined as selected compounds. All other compounds will remain proprietary to Licensor.

Licensee sourced compounds mean compounds supplied by Licensee to Licensor for the purpose of screening by Licensor pursuant to the Research Program in the HCV Replicase Assay.

Field of Use
The primary assay to be used in the research program will determine the inhibitory effects of compounds from Licensor or Licensee libraries on a truncated form of the Hepatitis C RNA polymerase.

The Parties wish to collaborate on the discovery and development of Hepatitis C inhibitors which act through the viral replicase enzyme.

IPSCIO Record ID: 369327

License Grant
Licensor hereby grants to Licensee a royalty-bearing, worldwide, exclusive license, with the right to sublicense (subject to Section 5.5), under Licensor Know-How and Exclusive Patents, solely to Develop Collaboration Leads and Commercialize Licensed Products in the Field.

The parties will collaborate to develop biopharmaceutical products containing one or more macrocycles.

License Property
Collaboration Compound shall mean any macrocycle compound developed or generated by or on behalf of either Party (or the Parties jointly) arising from activities conducted or permitted under this Agreement, and any Analog, derivative, salt, ester, polymorphic, stereoisomer, metabolite, pro-drug form of any such Collaboration Compound. For clarity, Collaboration Compounds shall include all Collaboration Hits (including all compounds provided by Licensor to Licensee as part of the NPY2 program) and Optimized Collaboration Hits and shall exclude all other compounds first synthesized by a Party prior to the Effective Date.

The term compound when used herein shall include the particular compound structure in question, its optical isomers, plus all solvates (including hydrates), salt forms and polymorphs of the foregoing.

Licensor Core Technology shall mean all Patents and Know-How Controlled by Licensor or any of its Affiliates covering or claiming the creation of macrocycle libraries using its MATCHâ„¢ Technology, the macrocycle compounds in Licensors HITCREATEâ„¢ Library, assay methods for interrogating or selecting HITCREATEâ„¢ Libraries or any Materials Controlled by Licensor and provided to Licensee under this Agreement. For clarity, neither the generation of compounds by Licensee that are derived from the HITCREATEâ„¢ Library nor any such derived compounds, shall be considered Licensor Core Technology.

The HITCREATEâ„¢ Library is a MATCHâ„¢ Based Drug Discovery Library consisting of 21,200 macrocycles available for screening as of the Effective Date of the Agreement.

Licensor Patents shall mean all Patents (other than Patents claiming any Licensor Core Technology) Controlled by Licensor or any of its Affiliates, and containing a Valid Claim Covering any of the Collaboration Compounds or Licensed Products. For clarity, Licensor Patents shall include, if applicable, Licensors interest in Patents within its Sole Research Program IP and within the Joint Research Program IP.

Collaboration Lead(s) shall mean any Collaboration Compound that binds to or has activity with regards to the applicable Collaboration Target and is designated as a Collaboration Lead, and in each case certain Analogs as described below, along with any derivative, salt, ester, polymorphic, stereoisomer, metabolite, pro-drug form of such Collaboration Compound. Upon designation of a Collaboration Lead, such designation shall include those Analogs of the selected Collaboration Compound, which exhibit the same structure-activity relationship with the applicable Collaboration Target, such structure-activity relationship as mutually agreed in good faith by the JSC, such agreement shall require approval of (a) both Parties representatives on the JSC or (b) if the term of the JSC has expired or Licensors participation on the JSC has ceased, then the approval of designees of each Party, in each case with a Partys consent not to be unreasonably withheld.

Field of Use
The collaboration will deploy Licensor’s proprietary drug discovery technology, Macrocyclic Template Chemistry (MATCH™), to identify and develop new drug candidates for multiple targets in diverse therapeutic areas.

The goal of the collaboration is to explore the molecular chemistry space accessed by MATCHâ„¢ to discover novel bioactive macrocycles. These macrocycles represent a distinct and underexplored compound class that displays favorable characteristics exhibited by large biomolecules, such as high potency and selectivity, while maintaining the benefits typically associated with small molecule drugs, such as high oral availability and low cost of goods. The collaboration will deploy Licensors proprietary drug discovery technology,

IPSCIO Record ID: 347053

License Grant
Included with this collaboration agreement is information for a third party license.  The collaboration is to screen the Materials against the Assays.

In the third party license, the University of Canada grants the use of the assay.

License Property
The assay is for the multidrug resistance protein.
Field of Use
Licensee has Assays which have the potential to identify therapeutic and/or diagnostic products.

IPSCIO Record ID: 367275

License Grant
With Respect to Library Compounds, Licensor grants a worldwide, non-exclusive license, under Licensor Intellectual Property, to use Library Compounds and Library Compound Information for research purposes in the discovery of Hits to Licensee Targets, performing Hit-to-Lead Chemistry Programs and Lead Optimization Programs and in the Development of Royalty-Bearing Products that contain Library Compounds, which license shall include the right to use Synthetic Methodology and Pathways solely to synthesize Library Compounds which have been identified as Hits and Library Compounds structurally related thereto, and Licensee Analogs that derive from such Library Compounds, for the purpose of performing Drug Discovery Programs.

With Respect to Analogs, Licensor grants a worldwide, perpetual, non-exclusive license, under Licensor Intellectual Property, to use Analogs and Licensee Analog Information in the discovery of Hits to Licensee Targets, performing Hit-to-Lead Chemistry Programs and Lead Optimization Programs and in the Development of Royalty-Bearing Products and Non-Royalty-Bearing Products that contain Analogs, which license shall include the right to use Synthetic Methodology and Pathways solely to synthesize Analogs.

License Property
Licensor Controls certain technology for the creation of large numbers of complex, natural-compound-like compounds for the purpose of screening biological targets to identify potential human therapeutics.

Target shall mean a protein or polypeptide, which is involved in a biological process as well as orthologs thereof and all isoforms or polymorphisms, including single nucleotide polymorphisms, alleles, and other naturally-occurring or synthetic derivatives, including, without limitation, insertions, additions, deletions, fragments and splice variants thereof and nucleic acid sequences encoding any of the above that is configured into one or more assays for screening, including, but not limited to, in vitro assays and phenotypic or pathway screens, cell-based or in vivo assays, or used for structure-based compound design.

Library Compound shall mean a compound that Licensor delivered pursuant to the Prior Agreement.

Library Compound Information shall mean structural, process or other information relating to a Library Compound.

Library Compound Structure Information shall mean documentation of the molecular formula and molecular structure of each Library Compound.

Hit shall mean a Library Compound or an Analog that is confirmed as active against a Licensee Target, or for which computational data is generated which predicts activity, which is subsequently confirmed as active against a Licensee Target.

A Licensee Analog is designed, discovered or synthesized by Licensee in the course of a Drug Discovery Program.

Synthetic Methodology and Pathways shall mean, with respect to a Library Compound, the synthetic scheme that Licensor used to synthesize the Library Compound,

Field of Use
The technology is used for the purpose of screening biological targets to identify potential human therapeutics.

IPSCIO Record ID: 332261

License Grant
Included with this collaboration agreement is information for a third party license.  The collaboration is to screen the Materials against the Assays.

In the third party license, the University grants the use of the assay.

License Property
The assay is for the mutant cystic fibrosis transmembrane regulator or CFTR.
Field of Use
Licensee has Assays which have the potential to identify therapeutic and/or diagnostic products.

IPSCIO Record ID: 249718

License Grant
Licensor grants an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and undivided interest in any Program Intellectual Property and Program Patent Rights that are jointly owned by Licensor and Licensee, as embodied in or related to Designated Compounds, to identify, research, develop, make, have made and use such Designated Compound to develop Licensed Products and to develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products; provided, that the exclusivity of such license shall be subject in the case of Generic Patent Rights to the retained rights.
License Property
The licensed property is
(a) the NeoMorph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Preliminary Compounds,
(e) the Primary Active Compounds,
(f) the Selected Compounds, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof made by Licensor, and
(g) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Programs.

The NeoMorph Screening Library consists of approximately 10,000,000 diverse small organic compounds.

Field of Use
Field means the diagnosis, prevention and/or treatment of any and all diseases in humans.

Licensor synthesize small molecule compounds as mixtures in a format that enables ALIS to efficiently screen proteins. Our proprietary NeoMorph library, consisting of over 10 million diverse small molecules, is stored as approximately 5,000 mixtures, each containing approximately 2,000 mass-encoded compounds. We use proprietary software to ensure that each small molecule compound within a mixture can be uniquely identified by its mass. This obviates the need for artificial tagging methods, which adds preparation time and cost, and may interfere with the screening process.

Under this drug discovery collaboration, Licensor agreed to screen a number of proteins supplied to us by Licensee. Licensor maintains the option to develop some or all of the small molecule compounds Licensor identify.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.